Skip to main content
. 2012 Dec;4(6):583–587. doi: 10.3978/j.issn.2072-1439.2012.11.02

Table 2. Lung function before and after Symbicort Turbuhaler (160/4.5 μg ×2) inhalation in patients with asthma and COPD (x±s).

Time (min) FEV1 (L) FVC (L) FEV1/FVC (%) IC (L) Predicted FEV1(%)
Asthma (n=30)   baseline
  3
  10
  30
1.46±0.48
1.70±0.53
1.82±0.57
1.82±0.61
2.69±0.73
3.02±0.76
3.11±0.82
3.17±0.82
54.29±10.70
56.53±11.65
56.69±11.93
57.45±13.28
1.96±0.57
2.15±0.65
2.27±0.66
2.37±0.68
      50.79±15.75
      59.48±17.92
      63.55±19.99
      63.13±19.72
COPD (n=62)   baseline
  3
  10
  30
1.16±0.52
1.24±0.46
1.27±0.48
1.28±0.49
2.11±0.62
2.39±0.59
2.46±0.58
2.49±0.57
50.61±10.57
50.93±12.12
50.57±12.05
50.40±12.57
1.70±0.62
1.80±0.54
1.86±0.51
1.86±0.48
      49.25±18.84
      53.27±19.03
      54.45±19.34
      54.90±19.89
Treatment main effect   F
  P
17.84
<0.001
19.67
<0.001
4.76
0.032
10.69
0.002
      2.31
      0.132
Time main effect   F
  P
60.46
<0.001
117.33
<0.001
3.78
0.017
18.15
<0.001
      64.63
      <0.001
Treatment × time interaction effect   F
  P
16.51
<0.001
1.40
0.25
4.28
0.01
3.11
0.045
      10.24
      <0.001

Notes: P values of all comparison of each time point after treatment comparing with baseline in asthma group were <0.05, indicates that P values of FEV1/FVC in each time point after treatment comparing with baseline in COPD group were >0.05, others were <0.05.